Development and validation of a single-cell network profiling assay-based classifier to predict response to induction therapy in paediatric patients with de novo acute myeloid leukaemia: A report from the children's oncology group

British Journal of Haematology

Volumn 162, Issue 2, 2013, Pages 250-262

  Lacayo, Norman J ^a,b   Alonzo, Todd A ^a,c   Gayko, Urte ^d   Rosen, David B ^d   Westfall, Matt ^d   Purvis, Norman ^d   Putta, Santosh ^d   Louie, Brent ^d   Hackett, James ^d   Cohen, Aileen Cleary ^d   Cesano, Alessandra ^d   Gerbing, Robert ^a   Ravindranath, Yaddanapudi ^a,e   Dahl, Gary V ^a,b   Gamis, Alan ^a,f   Meshinchi, Soheil ^a,g  

^a CHILDREN S ONCOLOGY GROUP   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d Nodality Inc   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

^f CHILDREN S MERCY HOSPITAL   (United States)

^g USA   (United States)

Author keywords

Induction response; Intracellular signalling; Paediatric acute myeloid leukaemia; Single cell network profiling

Indexed keywords

CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; TIOGUANINE;

ACCURACY; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD CELL COUNT; BONE MARROW BIOPSY; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; CYTOGENETICS; DRUG MEGADOSE; FEMALE; FLOW CYTOMETRY; GENETIC RISK; HUMAN; HUMAN CELL; INDUCTION CHEMOTHERAPY; INFANT; INTRACELLULAR SIGNALING; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROBABILITY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; RISK ASSESSMENT; SCHOOL CHILD; SINGLE CELL NETWORK PROFILING; VALIDATION STUDY;

INDUCTION RESPONSE; INTRACELLULAR SIGNALLING; PAEDIATRIC ACUTE MYELOID LEUKAEMIA; SINGLE CELL NETWORK PROFILING;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYTARABINE; DAUNORUBICIN; FEMALE; FLOW CYTOMETRY; HUMANS; INFANT; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEUKEMIA, MYELOID, ACUTE; MALE; NEOADJUVANT THERAPY; PROGNOSIS; PROSPECTIVE STUDIES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SINGLE-CELL ANALYSIS; THIOGUANINE; TREATMENT OUTCOME;

EID: 84879843884     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12370     Document Type: Article

References (53)

1. Agresti, A. (1992) A survey of exact inference for contingency tables. Statistical Science, 7, 46.
2. Becton, D., Dahl, G.V., Ravindranath, Y., Chang, M.N., Behm, F.G., Raimondi, S.C., Head, D.R., Stine, K.C., Lacayo, N.J., Sikic, B.I., Arceci, R.J. & Weinstein, H. (2006) Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421. Blood, 107, 1315-1324.
3. Bendall, S.C., Simonds, E.F., Qiu, P., el Amir, A.D., Krutzik, P.O., Finck, R., Bruggner, R.V., Melamed, R., Trejo, A., Ornatsky, O.I., Balderas, R.S., Plevritis, S.K., Sachs, K., Pe'er, D., Tanner, S.D. & Nolan, G.P. (2011) Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science, 332, 687-696.
4. Berman, J.N., Gerbing, R.B., Alonzo, T.A., Ho, P.A., Miller, K., Hurwitz, C., Heerema, N.A., Hirsch, B., Raimondi, S.C., Lange, B., Franklin, J.L., Gamis, A. & Meshinchi, S. (2011) Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group. Leukemia, 25, 1039-1042.
5. Breems, D.A. & Lowenberg, B. (2011) Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum. Haematologica, 96, 491-493.
6. Breems, D.A., Van Putten, W.L., De Greef, G.E., Van Zelderen-Bhola, S.L., Gerssen-Schoorl, K.B., Mellink, C.H., Nieuwint, A., Jotterand, M., Hagemeijer, A., Beverloo, H.B. & Lowenberg, B. (2008) Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. Journal of Clinical Oncology, 26, 4791-4797.
7. Breiman, L. (2001) Random forests. Machine Learning, 45, 5-32.
8. Brown, P., Meshinchi, S., Levis, M., Alonzo, T.A., Gerbing, R., Lange, B., Arceci, R. & Small, D. (2004) Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition. Blood, 104, 1841-1849.
9. Cesano, A., Rosen, D.B., O'Meara, P., Putta, S., Gayko, U., Spellmeyer, D.C., Cripe, L.D., Sun, Z., Uno, H., Litzow, M.R., Tallman, M.S. & Paietta, E. (2012) Functional pathway analysis in acute myeloid leukemia using single cell network profiling assay: effect of specimen source (bone marrow or peripheral blood) on assay readouts. Cytometry. Part B, Clinical Cytometry, 82, 158-172.
10. Cheson, B.D., Bennett, J.M., Kopecky, K.J., Buchner, T., Willman, C.L., Estey, E.H., Schiffer, C.A., Doehner, H., Tallman, M.S., Lister, T.A., Lo-Coco, F., Willemze, R., Biondi, A., Hiddemann, W., Larson, R.A., Lowenberg, B., Sanz, M.A., Head, D.R., Ohno, R. & Bloomfield, C.D. (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for therapeutic trials in acute myeloid leukemia. Journal of Clinical Oncology, 21, 4642-4649.
11. Cooper, T.M., Franklin, J., Gerbing, R.B., Alonzo, T.A., Hurwitz, C., Raimondi, S.C., Hirsch, B., Smith, F.O., Mathew, P., Arceci, R.J., Feusner, J., Iannone, R., Lavey, R.S., Meshinchi, S. & Gamis, A. (2012) AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer, 118, 761-769.
12. Efron, B.T. & Robert, J. (1993) An Introduction to Bootstrap. Chapman and Hall, Boca Raton, FL.
13. Firth, D. (1993) Bias reduction of maximum likelihood estimates. Biometrika, 80, 41.
14. Gentles, A.J., Plevritis, S.K., Majeti, R. & Alizadeh, A.A. (2010) Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA, 304, 2706-2715.
15. Gibbs, K.D. Jr, Gilbert, P.M., Sachs, K., Zhao, F., Blau, H.M., Weissman, I.L., Nolan, G.P. & Majeti, R. (2011) Single-cell phospho-specific flow cytometric analysis demonstrates biochemical and functional heterogeneity in human hematopoietic stem and progenitor compartments. Blood, 117, 4226-4233.
16. Harrell, F.E. Jr. (2001) Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. Springer-Verlag, New York.
17. Ho, P.A., Alonzo, T.A., Gerbing, R.B., Pollard, J., Stirewalt, D.L., Hurwitz, C., Heerema, N.A., Hirsch, B., Raimondi, S.C., Lange, B., Franklin, J.L., Radich, J.P. & Meshinchi, S. (2009) Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood, 113, 6558-6566.
18. Ho, P.A., Alonzo, T.A., Kopecky, K.J., Miller, K.L., Kuhn, J., Zeng, R., Gerbing, R.B., Raimondi, S.C., Hirsch, B.A., Oehler, V., Hurwitz, C.A., Franklin, J.L., Gamis, A.S., Petersdorf, S.H., Anderson, J.E., Reaman, G.H., Baker, L.H., Willman, C.L., Bernstein, I.D., Radich, J.P., Appelbaum, F.R., Stirewalt, D.L. & Meshinchi, S. (2010) Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia, 24, 909-913.
19. Ho, P.A., Kutny, M.A., Alonzo, T.A., Gerbing, R.B., Joaquin, J., Raimondi, S.C., Gamis, A.S. & Meshinchi, S. (2011) Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group. Pediatric Blood & Cancer, 57, 204-209.
20. Hollander, M. & Wolfe, D.A. (1999) Nonparametric Statistical Methods. xiv+787 pages. John Wyley and Sons, Inc, New York.
21. Hotson, A.N., Hardy, J.W., Hale, M.B., Contag, C.H. & Nolan, G.P. (2009) The T cell STAT signaling network is reprogrammed within hours of bacteremia via secondary signals. Journal of Immunology, 182, 7558-7568.
22. Irish, J.M., Hovland, R., Krutzik, P.O., Perez, O.D., Bruserud, O., Gjertsen, B.T. & Nolan, G.P. (2004) Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell, 118, 217-228.
23. Irish, J.M., Czerwinski, D.K., Nolan, G.P. & Levy, R. (2006a) Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood, 108, 3135-3142.
24. Irish, J.M., Kotecha, N. & Nolan, G.P. (2006b) Mapping normal and cancer cell signalling networks: towards single-cell proteomics. Nature Reviews Cancer, 6, 146-155.
25. Irish, J.M., Myklebust, J.H., Alizadeh, A.A., Houot, R., Sharman, J.P., Czerwinski, D.K., Nolan, G.P. & Levy, R. (2010) B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 107, 12747-12754.
26. Jan, M., Chao, M.P., Cha, A.C., Alizadeh, A.A., Gentles, A.J., Weissman, I.L. & Majeti, R. (2011) Prospective separation of normal and leukemic stem cells based on differential expression of TIM3, a human acute myeloid leukemia stem cell marker. Proceedings of the National Academy of Sciences of the United States of America, 108, 5009-5014.
27. Kornblau, S.M., Tibes, R., Qiu, Y.H., Chen, W., Kantarjian, H.M., Andreeff, M., Coombes, K.R. & Mills, G.B. (2009) Functional proteomic profiling of AML predicts response and survival. Blood, 113, 154-164.
28. Kornblau, S.M., Minden, M.D., Rosen, D.B., Putta, S., Cohen, A., Covey, T., Spellmeyer, D.C., Fantl, W.J., Gayko, U. & Cesano, A. (2010a) Dynamic single-cell network profiles in acute myelogenous leukemia are associated with patient response to standard induction therapy. Clinical Cancer Research, 16, 3721-3733.
29. Kornblau, S.M., McCue, D., Singh, N., Chen, W., Estrov, Z. & Coombes, K.R. (2010b) Recurrent expression signatures of cytokines and chemokines are present and are independently prognostic in acute myelogenous leukemia and myelodysplasia. Blood, 116, 4251-4261.
30. Kotecha, N., Flores, N.J., Irish, J.M., Simonds, E.F., Sakai, D.S., Archambeault, S., Diaz-Flores, E., Coram, M., Shannon, K.M., Nolan, G.P. & Loh, M.L. (2008) Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell, 14, 335-343.
31. Krutzik, P.O. & Nolan, G.P. (2006) Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nature Methods, 3, 361-368.
32. Krutzik, P.O., Irish, J.M., Nolan, G.P. & Perez, O.D. (2004) Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clinical Immunology, 110, 206-221.
33. Lacayo, N.J., Meshinchi, S., Kinnunen, P., Yu, R., Wang, Y., Stuber, C.M., Douglas, L., Wahab, R., Becton, D.L., Weinstein, H., Chang, M.N., Willman, C.L., Radich, J.P., Tibshirani, R., Ravindranath, Y., Sikic, B.I. & Dahl, G.V. (2004) Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood, 104, 2646-2654.
34. Liaw, A. & Wiener, M. (2002) Classifications and regression by random forest. R News, 2, 18-22.
35. Loken, M.R., Alonzo, T.A., Pardo, L., Gerbing, R.B., Raimondi, S.C., Hirsch, B.A., Ho, P.A., Franklin, J., Cooper, T.M., Gamis, A.S. & Meshinchi, S. (2012) Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood, 120, 1581-1588.
36. Majeti, R. & Weissman, I.L. (2011) Human acute myelogenous leukemia stem cells revisited: there's more than meets the eye. Cancer Cell, 19, 9-10.
37. Majeti, R., Becker, M.W., Tian, Q., Lee, T.L., Yan, X., Liu, R., Chiang, J.H., Hood, L., Clarke, M.F. & Weissman, I.L. (2009) Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Proceedings of the National Academy of Sciences of the United States of America, 106, 3396-3401.
38. Mason, S.J. & Graham, N.E. (2002) Areas beneath the relative operating characteristics (ROC) and relative operating levels (ROL) curves: statistical significance and interpretation. Quarterly Journal of the Royal Meteorological Society, 128, 21.
39. Meshinchi, S., Woods, W.G., Stirewalt, D.L., Sweetser, D.A., Buckley, J.D., Tjoa, T.K., Bernstein, I.D. & Radich, J.P. (2001) Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood, 97, 89-94.
40. O'Donnell, M.R., Abboud, C.N., Altman, J., Appelbaum, F.R., Coutre, S.E., Damon, L.E., Foran, J.M., Goorha, S., Maness, L.J., Marcucci, G., Maslak, P., Millenson, M.M., Moore, J.O., Ravandi, F., Shami, P.J., Smith, B.D., Stone, R.M., Strickland, S.A., Tallman, M.S. & Wang, E.S.; National Comprehensive Cancer Network. (2011) NCCN clinical practice guidelines in oncology: acute myeloid leukemia. Journal of the National Comprehensive Cancer Network, 9, 280-317.
41. Pepe, M.S. (2003) The Statistical Evaluation of Medical Tests for Classification and Prediction. Oxford University Press, Oxford.
42. Perez, O.D. & Nolan, G.P. (2006) Phospho-proteomic immune analysis by flow cytometry: from mechanism to translational medicine at the single-cell level. Immunological Reviews, 210, 208-228.
43. Pollard, J.A., Alonzo, T.A., Gerbing, R.B., Ho, P.A., Zeng, R., Ravindranath, Y., Dahl, G., Lacayo, N.J., Becton, D., Chang, M., Weinstein, H.J., Hirsch, B., Raimondi, S.C., Heerema, N.A., Woods, W.G., Lange, B.J., Hurwitz, C., Arceci, R.J., Radich, J.P., Bernstein, I.D., Heinrich, M.C. & Meshinchi, S. (2010) Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood, 115, 2372-2379.
44. Pui, C.H., Carroll, W.L., Meshinchi, S. & Arceci, R.J. (2011) Biology, risk stratification, and therapy of pediatric acute leukemias: an update. Journal of Clinical Oncology, 29, 551-565.
45. Razzouk, B.I., Estey, E., Pounds, S., Lensing, S., Pierce, S., Brandt, M., Rubnitz, J.E., Ribeiro, R.C., Rytting, M., Pui, C.H., Kantarjian, H. & Jeha, S. (2006) Impact of age on outcome of pediatric acute myeloid leukemia: a report from 2 institutions. Cancer, 106, 2495-2502.
46. Rosen, D.B., Minden, M.D., Kornblau, S.M., Cohen, A., Gayko, U., Putta, S., Woronicz, J., Evensen, E., Fantl, W.J. & Cesano, A. (2010a) Functional characterization of FLT3 receptor signaling deregulation in acute myeloid leukemia by single cell network profiling (SCNP). PLoS ONE, 5, e13543.
47. Rosen, D.B., Putta, S., Covey, T., Huang, Y.W., Nolan, G.P., Cesano, A., Minden, M.D. & Fantl, W.J. (2010b) Distinct patterns of DNA damage response and apoptosis correlate with Jak/Stat and PI3kinase response profiles in human acute myelogenous leukemia. PLoS ONE, 5, e12405.
48. Rubnitz, J.E., Inaba, H., Dahl, G., Ribeiro, R.C., Bowman, W.P., Taub, J., Pounds, S., Razzouk, B.I., Lacayo, N.J., Cao, X., Meshinchi, S., Degar, B., Airewele, G., Raimondi, S.C., Onciu, M., Coustan-Smith, E., Downing, J.R., Leung, W., Pui, C.H. & Campana, D. (2010) Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. The Lancet Oncology, 11, 543-552.
49. Sachs, K., Perez, O., Pe'er, D., Lauffenburger, D.A. & Nolan, G.P. (2005) Causal protein-signaling networks derived from multiparameter single-cell data. Science, 308, 523-529.
50. Stelzer, G. & Goodpasture, L. (2000) Use of Multiparameter Flow Cytometry and Immunophenotyping for the Diagnosis and Classification of Acute Myeloid Leukemia. Wiley-Liss, Wilmington, DE.
51. Stirewalt, D.L., Kopecky, K.J., Meshinchi, S., Appelbaum, F.R., Slovak, M.L., Willman, C.L. & Radich, J.P. (2001) FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood, 97, 3589-3595.
52. Tsukimoto, I., Tawa, A., Horibe, K., Tabuchi, K., Kigasawa, H., Tsuchida, M., Yabe, H., Nakayama, H., Kudo, K., Kobayashi, R., Hamamoto, K., Imaizumi, M., Morimoto, A., Tsuchiya, S. & Hanada, R. (2009) Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. Journal of Clinical Oncology, 27, 4007-4013.
53. Zwaan, C.M., Meshinchi, S., Radich, J.P., Veerman, A.J., Huismans, D.R., Munske, L., Podleschny, M., Hahlen, K., Pieters, R., Zimmermann, M., Reinhardt, D., Harbott, J., Creutzig, U., Kaspers, G.J. & Griesinger, F. (2003) FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood, 102, 2387-2394.